KROS Live signals | Maximize Profits with Getagraph.com

SELL 101239 min ago

@ $58.15

Issued: 14 Feb 2024 @ 15:11

Return: -3.28%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 4.68 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	252 367
Average Volume	370 124
Market Cap	2.02B
EPS	$-1.340 ( 2024-03-01 )
Next earnings date	( $-1.310 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-10.82
ATR14	$0.0820 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-23	Seehra Jasbir	Buy	125 000	Employee Stock Option (right to buy)
2024-02-13	Seehra Jasbir	Buy	125 000	Employee Stock Option (right to buy)
2024-02-13	Regnante Keith	Buy	40 000	Employee Stock Option (right to buy)
2024-02-13	Rovaldi Christopher	Buy	150 000	Employee Stock Option (right to buy)
2024-02-13	Cooper Simon Peter	Buy	40 000	Employee Stock Option (right to buy)

INSIDER POWER
67.56
Last 96 transactions
Buy: 1 546 013 \| Sell: 365 314

Volume Correlation

Long: -0.04 (neutral)

Short: -0.82 (strong negative)

Signal:(37.818) Neutral

Keros Therapeutics Inc Correlation

10 Most Positive Correlations
PRAX	0.919
CDNA	0.904
HNNA	0.894
RPAY	0.889
TTEC	0.888
EWTX	0.883
SMSI	0.882
SRAX	0.879
ANNX	0.876
LPCN	0.874

10 Most Negative Correlations
CNST	-0.811
UNCY	-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Keros Therapeutics Inc Correlation - Currency/Commodity

0.18
( neutral )

-0.34
( neutral )

0.00
( neutral )

-0.07
( neutral )

-0.59
( weak negative )

-0.06
( neutral )

Keros Therapeutics Inc Financials

Annual	2023
Revenue:	$151 000
Gross Profit:	$-664 000 (-439.74 %)
EPS:	$-5.20

Q4	2023
Revenue:	$143 000
Gross Profit:	$-104 000 (-72.73 %)
EPS:	$-1.340

Q3	2023
Revenue:	$8 000.00
Gross Profit:	$-543 000 (-6 787.50 %)
EPS:	$-1.330

Q2	2023
Revenue:	$0
Gross Profit:	$-545 000 (0.00 %)
EPS:	$-1.270

Financial Reports:

No articles found.

Keros Therapeutics Inc

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.